Generic breast cancer drug approved for launch
Jun 9, 2011
APP Pharma will produce a generic equivalent to Novartis' Femara drug, which helps treat breast cancer by blocking hormones in a process called aromatase inhibition, according to a new report from Business Week.
Femara is marketed toward older women in order to decrease the chances of cancer recurrence in post-menopausal patients.
Several other drugs perform similar functions in the fight against breast cancer, such as Aromasin and Arimidex, the former of which already has generic versions that are on the market.
APP is owned by Fresenius Kabi Pharmaceuticals Holding Inc. The U.S. Food and Drug Administration recently approved APP's generic form of the Femara drug.
Femara earned annual revenues of $619.4 million in the U.S. last year, according to the news outlet.
More than 200,000 women were diagnosed with breast cancer in 2010, according to BreastCancer.org. According to the American Cancer Society, one in eight women in the U.S. will be diagnosed with breast cancer at some point in her lifetime. As a result, the American Cancer Society recommends that all women over 40 visit their doctor for annual mammograms.